Viviana Cortlana, Jade Gambill, Jenna Ghazal, Kennedy Itodo, Shreevikaa Kannan, Yan Leyfman, Chandler H Park
{"title":"拓展 T 细胞淋巴瘤治疗的视野:关注个性化治疗策略。","authors":"Viviana Cortlana, Jade Gambill, Jenna Ghazal, Kennedy Itodo, Shreevikaa Kannan, Yan Leyfman, Chandler H Park","doi":"10.46883/2025.25921036","DOIUrl":null,"url":null,"abstract":"<p><p>T-cell lymphoma, a form of non-Hodgkin lymphoma, presents significant treatment challenges due to its diverse subtypes and aggressive progression. Jasmine Zain, MD, drawing on her expertise in chimeric antigen receptors (CAR) T-cell therapies, is focused on expanding therapeutic options for T-cell lymphomas, particularly peripheral T-cell lymphoma (PTCL). A critical aspect of treatment development involves recognizing that the subtypes of nodal PTCL are defined by specific genetic pathways, which determine their response to different therapies. This insight has led to the development of more personalized, subtype-specific treatment strategies. Current treatment approaches for PTCL typically involve combinations of chemotherapy, targeted therapies, immunotherapy, and stem cell transplantation. The standard first-line therapy, CHOP (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone), has relatively low response rates, highlighting the need for more effective alternatives. While stem cell transplantation is beneficial for certain PTCL subtypes, overall outcomes remain inconsistent. Some targeted therapies have shown efficacy in specific subtypes, but many forms of PTCL are still resistant to available treatments, underscoring the need for further research. In cases of relapsed/refractory disease, stem cell transplantation remains the primary treatment option, though it is associated with significant risks and often impacts patients' quality of life. There is a pressing need for new, less toxic therapies. Several targeted drugs are currently in clinical trials, with the goal of improving treatment options for patients with relapsed/refractory PTCL. Ongoing research into the genetic and molecular characteristics of PTCL aims to develop more individualized therapies that are better suited to each patient's specific disease profile, offering hope for improved outcomes in this challenging lymphoma subtype.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 2","pages":"80-84"},"PeriodicalIF":1.8000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies.\",\"authors\":\"Viviana Cortlana, Jade Gambill, Jenna Ghazal, Kennedy Itodo, Shreevikaa Kannan, Yan Leyfman, Chandler H Park\",\"doi\":\"10.46883/2025.25921036\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>T-cell lymphoma, a form of non-Hodgkin lymphoma, presents significant treatment challenges due to its diverse subtypes and aggressive progression. Jasmine Zain, MD, drawing on her expertise in chimeric antigen receptors (CAR) T-cell therapies, is focused on expanding therapeutic options for T-cell lymphomas, particularly peripheral T-cell lymphoma (PTCL). A critical aspect of treatment development involves recognizing that the subtypes of nodal PTCL are defined by specific genetic pathways, which determine their response to different therapies. This insight has led to the development of more personalized, subtype-specific treatment strategies. Current treatment approaches for PTCL typically involve combinations of chemotherapy, targeted therapies, immunotherapy, and stem cell transplantation. The standard first-line therapy, CHOP (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone), has relatively low response rates, highlighting the need for more effective alternatives. While stem cell transplantation is beneficial for certain PTCL subtypes, overall outcomes remain inconsistent. Some targeted therapies have shown efficacy in specific subtypes, but many forms of PTCL are still resistant to available treatments, underscoring the need for further research. In cases of relapsed/refractory disease, stem cell transplantation remains the primary treatment option, though it is associated with significant risks and often impacts patients' quality of life. There is a pressing need for new, less toxic therapies. Several targeted drugs are currently in clinical trials, with the goal of improving treatment options for patients with relapsed/refractory PTCL. Ongoing research into the genetic and molecular characteristics of PTCL aims to develop more individualized therapies that are better suited to each patient's specific disease profile, offering hope for improved outcomes in this challenging lymphoma subtype.</p>\",\"PeriodicalId\":51147,\"journal\":{\"name\":\"Oncology-New York\",\"volume\":\"39 2\",\"pages\":\"80-84\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology-New York\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.46883/2025.25921036\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology-New York","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46883/2025.25921036","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies.
T-cell lymphoma, a form of non-Hodgkin lymphoma, presents significant treatment challenges due to its diverse subtypes and aggressive progression. Jasmine Zain, MD, drawing on her expertise in chimeric antigen receptors (CAR) T-cell therapies, is focused on expanding therapeutic options for T-cell lymphomas, particularly peripheral T-cell lymphoma (PTCL). A critical aspect of treatment development involves recognizing that the subtypes of nodal PTCL are defined by specific genetic pathways, which determine their response to different therapies. This insight has led to the development of more personalized, subtype-specific treatment strategies. Current treatment approaches for PTCL typically involve combinations of chemotherapy, targeted therapies, immunotherapy, and stem cell transplantation. The standard first-line therapy, CHOP (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone), has relatively low response rates, highlighting the need for more effective alternatives. While stem cell transplantation is beneficial for certain PTCL subtypes, overall outcomes remain inconsistent. Some targeted therapies have shown efficacy in specific subtypes, but many forms of PTCL are still resistant to available treatments, underscoring the need for further research. In cases of relapsed/refractory disease, stem cell transplantation remains the primary treatment option, though it is associated with significant risks and often impacts patients' quality of life. There is a pressing need for new, less toxic therapies. Several targeted drugs are currently in clinical trials, with the goal of improving treatment options for patients with relapsed/refractory PTCL. Ongoing research into the genetic and molecular characteristics of PTCL aims to develop more individualized therapies that are better suited to each patient's specific disease profile, offering hope for improved outcomes in this challenging lymphoma subtype.
期刊介绍:
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.